Fig. 5
From: VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy
Effects of CB-5083 in CNS of VCPR155H/R155H mice. Whole-brain lysates (A) and spinal cords lysates (B) from WT, vehicle-treated and CB-5083-treated VCPR155H/R155H mice (n = 3 per group) were subjected to immunoblotting using antibodies against TDP-43 and GAPDH. The TDP-43 level was not altered upon CB-5083 treatment. C Quantification of Western blots shown in (A, B). D Motor neuron lesions were identified in spinal cords of VCPR155H/R155H mice treated with either CB-5083 or vehicle. Arrowhead points to the injured neurons. Western blot was repeated three times. Statistical analysis was performed by one-way ANOVA followed by Fisher’s LSD test *P < 0.05